Literature DB >> 12394602

Daily haemodialysis for acute renal failure.

Helmut Schiffl1.   

Abstract

PURPOSE OF REVIEW: Current guidelines on dialysis adequacy for patients with acute renal failure are based upon extrapolation from end-stage renal disease. As a result, intermittent haemodialysis - the most commonly used modality of renal replacement therapy - is typically prescribed for 3 or 4 h three or more times per week. Recent data suggest that alternate day dialysis provides inadequate dialysis dosing in the majority of critically ill patients. RECENT
FINDINGS: Measurements of urea kinetic modelling show that the delivered dose of dialysis is 20-30% lower than the prescribed dose and even less than adequate for a stable end-stage renal disease patient receiving haemodialysis three times per week. A recently published prospective comparison of two dialysis intensities (alternate day versus daily) demonstrated an association between increased treatment dose and improved outcome in critically ill patients. The beneficial effects of daily dialysis could be explained by lower uraemic toxicity, less fluid overload and a shorter duration of severe acute renal failure.
SUMMARY: The limited data on the effects of dialysis dose on acute renal failure suggest that the relationship between acute renal failure comorbid conditions and death in critically ill patients is more complicated than generally recognized. There is no doubt that alternate day dialysis provides a suboptimal dose of dialysis with negative impact on the outcome. Significant differences render the use of most urea kinetic modelling equations problematic. Despite the current lack of further information we would recommend that haemodialysis should be dosed daily in many cases of hypercatabolic or anuric acute renal failure.

Entities:  

Mesh:

Year:  2002        PMID: 12394602     DOI: 10.1097/00041552-200211000-00003

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  2 in total

1.  MicroRNA-494 reduces ATF3 expression and promotes AKI.

Authors:  Yi-Fan Lan; Hsi-Hsien Chen; Pei-Fang Lai; Ching-Feng Cheng; Yen-Ta Huang; Yi-Chao Lee; Tzen-Wen Chen; Heng Lin
Journal:  J Am Soc Nephrol       Date:  2012-11-15       Impact factor: 10.121

Review 2.  Current practice of conventional intermittent hemodialysis for acute kidney injury.

Authors:  H Schiffl; S M Lang
Journal:  Indian J Nephrol       Date:  2013-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.